Continuous Glucose Monitors (CGMs)

Healthcare · §614

A coin-sized patch on your upper arm estimates your blood sugar every few minutes for two weeks — that's a continuous glucose monitor, and since 2024 in the US you can buy one without a prescription (Dexcom Stelo, Abbott Lingo, about $89 for a two-sensor pack). The pitch is metabolic insight: see your own response to a bagel, a run, a glass of wine, a bad night's sleep. The reality is narrower — a useful two-to-four-week research project on your own body, real evidence in diabetes, almost no evidence that non-diabetic wear changes anything beyond the wear window, and a small but real chance of anxiety harm. Wear one or two sensors with a question, then take it off.

Test · Course Evidence Mixed Chapter Healthcare

The win is a sharper personal model — which of your meals actually spike you, whether a ten-minute walk after dinner does what people say, what alcohol does to your overnight floor. The catch is that nobody has shown this changes a single health number a month after you take the sensor off. Stick to two or three sensors with a specific question. Skip if you have any eating-disorder history; the constant numerical feedback is not safe in that direction.

The patch holds a hair-thin filament that sits in the fluid between your skin cells (not in your blood) and measures the glucose dissolved in it. The number on your phone is that fluid value, smoothed and offset to estimate what's in your bloodstream. Two consequences flow from this. First, there's a real lag — the fluid catches up to your blood about 5–10 minutes behind during quick changes, longer during exercise Klonoff 2017. Second, accuracy is a model, not a measurement: modern consumer sensors disagree with a fingerstick by roughly 10–15 mg/dL on any single reading. The shape of your curve over hours is what's reliable. The exact value at 2:47pm is not.

The reason CGMs exist as a category is that two people can eat the identical breakfast and one's glucose climbs to 130 mg/dL while the other's hits 180 mg/dL — same body weight, same age, same fasting blood sugar Zeevi et al. 2015 Berry et al. 2020. That gap is mostly invisible to fasting glucose, to HbA_1c, and to how you feel that morning. The CGM is the only practical tool that surfaces it without poking yourself a hundred times in a week.

What we actually know

In diabetes, the evidence is settled. Adults with type 1 diabetes who switch from fingersticks to a CGM lower their long-term average glucose meaningfully and spend less time dangerously low. In type 2 diabetes on basal insulin, the gain is smaller but real — and in the first 90 days after a type 2 diagnosis, a sensor turns abstract dietary advice into your own glucose data.

Outside diabetes — which is the whole reason Stelo and Lingo exist as over-the-counter products — the evidence map looks very different. Three findings are real and replicated. People differ. The same standard meal raises one person's glucose mildly and another's dramatically Zeevi et al. 2015 Berry et al. 2020. Roughly 15% of nominally healthy adults — normal HbA_1c, normal fasting glucose, no diabetes diagnosis — run patterns the standard tests miss, spending small but non-trivial fractions of the day above 140 mg/dL Hall et al. 2018. And sleep, exercise, and meal timing nudge your next-morning response in reproducible ways Tsereteli et al. 2022.

What's missing is the trial that would justify the marketing. Nobody has shown that wearing a CGM as a healthy adult improves a single hard health number — not HbA_1c, not weight, not blood pressure, not cholesterol — a month or a year after you take it off. Nobody has compared CGM-guided dietary advice to plain dietary advice in non-diabetics and found CGM ahead. The case for non-diabetic use is built from mechanism, from the diabetes trials, and from the variability findings — extrapolated. That's not the same as evidence the device makes you healthier.

How to actually use one

Wear it with a question. Two or three sensors — four to six weeks total — gets a non-diabetic adult almost every piece of useful information the device will ever produce. Past that point, what you're paying for is the screen in your pocket, not new knowledge.

Sensor 1, days 1–3. Don't change anything. Eat and live the way you normally do. You're learning your baseline — your overnight floor, your fasting morning value, the shape of your typical day.
Sensor 1, days 4–14. Log your meals (a phone photo is enough) plus the rough context: caffeine, exercise within the prior hour, sleep last night, alcohol the night before. Flag anything that peaks above 140 mg/dL or stays elevated for more than an hour.
Sensor 2, days 14–28. Run small experiments. The same lunch with and without a 10-minute walk after. White rice vs basmati vs the same calories in lentils. Your usual breakfast at 7am vs 10am. A hard workout the morning of vs the night before. Two beers with dinner vs no alcohol.
End. Take what you learned — usually two or three persistent dietary changes and a confirmed lifestyle tweak — and stop wearing the sensor.

For reference: a healthy adult's day, on average, runs a 24-hour mean of about 95–105 mg/dL, a fasting value of 70–100 mg/dL, and crosses 140 mg/dL maybe a few percent of the time Shah et al. 2019 Battelino et al. 2019. A single spike to 160 after a doughnut is normal. A flat line is not the target.

When not to wear one

The device itself is low-risk — a sticky patch and a tiny filament. The genuine harms are psychological and behavioural.

Any eating-disorder history. Anorexia, bulimia, orthorexia, binge-eating — past or present. A constant numerical readout that responds to every bite maps directly onto restrictive and ritualised eating patterns. Don't.
Health anxiety or somatic preoccupation. If you already check your pulse, monitor your sleep score, and notice every twinge, adding a glucose readout to that loop is a known trap.
You take insulin or sulfonylureas. The over-the-counter sensors are not validated for adjusting diabetes medication, and their accuracy below 70 mg/dL is poorer where the lag matters most Klonoff 2017. Use the prescription device your endocrinologist recommends, not the pharmacy-shelf one.
Pregnancy. Consumer CGMs are not validated for managing gestational diabetes. Your obstetrician's monitoring plan is the right one.

What the consumer apps will tell you that isn't true

A spike isn't pre-diabetes. Healthy young adults regularly cross 140 mg/dL after a bagel; the published reference cohorts established this Shah et al. 2019 Hall et al. 2018. A single post-meal peak isn't a disease marker. The clinical flag is sustained pattern — time above 140 mg/dL in the high single digits across multiple sensors, combined with a creeping fasting glucose or a rising HbA_1c. That conversation belongs in a clinic, not in an app notification.

Flat lines aren't the goal. The "any rise is bad" framing — sometimes called flat-line evangelism — has no support in the trial literature for healthy people. A modest rise after a normal meal is what a working metabolism looks like. The thing that matters is how high, how long, and how often, not whether the line moved.

The number isn't your blood sugar. It's a smoothed estimate from the fluid under your skin, lagging your blood by minutes. A fast swing during a workout, a low reading after you slept on the sensor for an hour, a wild value in the first day after insertion — these are usually sensor behaviour, not metabolic events.

The data isn't a meal plan. Your peak to oatmeal being higher than your peak to eggs is real information. Whether changing your breakfast on that basis makes you live longer or feel better in three months has not been tested in a healthy adult, anywhere Berry et al. 2020.

Where this goes sideways

You take the sensor off and your habits drift back within weeks. The biofeedback works while the screen is in your pocket. Nobody has shown the behaviour change persists. The way to handle this is to bank the two or three real lessons from your wear — the specific food you swap, the post-meal walk you now take — and accept that the rest will fade. Don't fight it by buying another sensor.

Every meal starts to feel like a test. The Reddit threads on consumer CGM are full of this: a healthy person who started curious and ended up afraid to eat fruit. If you notice the device occupying more of your headspace than your meals deserve, take it off early. The two-week wear is not a commitment.

You mistake a normal peak for a medical problem. A 165 mg/dL spike after a doughnut and a coffee, in a healthy 32-year-old, is not a finding. The cohort data shows the same in healthy controls Hall et al. 2018. The third-party apps that score this as "poor metabolic response" are running an aesthetic, not the evidence.

You mistake a sensor artefact for a glucose event. The first 12–24 hours of a fresh sensor are often inaccurate. Compression — sleeping on the sensor or lying on it on the couch — produces false lows. Rapid swings during exercise are partly the fluid-lag, not your blood. Two readings on a fingerstick will tell you whether the screen is wrong, when you genuinely need to know.

What you could do instead

If the actual question is "am I metabolically healthy?", fasting glucose and HbA_1c from an annual blood draw answer it cheaper, faster, and with a validated threshold for "you have a problem." The exception is when the HbA_1c itself is unreliable — some blood and kidney conditions throw the number off — where a CGM becomes the genuine workaround. Add a two-hour oral glucose tolerance test if your doctor flags borderline numbers. This is the screening pathway every endocrinology guideline still rests on, including for non-diabetic adults at risk ADA 2024.

If the actual question is "which of my meals do specific things to me?", a CGM is the right tool — and a two-to-four-week wear is the right dose. You can approximate it with a glucometer and four fingersticks per meal for a week, but that's nine pokes a day and a lot of paperwork; the CGM is genuinely better for the food-mapping use case.

If the actual question is "do I have metabolic problems my standard labs aren't catching?", fasting insulin, a fasting triglyceride-to-HDL ratio, ApoB, and waist circumference will surface most of what you'd care about. None of them require a wearable.

The smartwatches and rings that advertise "glucose insights" are not measuring glucose. As of 2024–2025, no consumer wearable has clearance for non-invasive glucose monitoring; the screens are inferring patterns from heart rate and skin temperature. Useful or not, this is not a CGM.

What you actually walk away with

Within the first week the surprise lands. The smoothie you considered healthy peaks you harder than the omelette. The 10-minute walk after lunch flattens an afternoon that used to drag. Late wine and a 9pm dinner together push your overnight floor twenty points higher than either alone. The patterns are reproducible — eat the same meal twice and your body draws the same curve Zeevi et al. 2015.

By the end of the second week, a 35-year-old who runs the variability pattern the Stanford cohort labelled "moderate" or "severe" — about 15% of nominally healthy adults Hall et al. 2018 — has identified the two or three meals that were costing them an afternoon, and the partner is the first to notice: the meeting after lunch goes better, the mid-afternoon snack stops being inevitable. For the other 85% the data is reassuring in a duller way: a normal-looking curve, a confirmed sense that the standard advice holds.

Three months out, with the sensor long gone, two or three persistent changes survive — a different breakfast, a walk after dinner, a different default at the work cafeteria. The flatter afternoon hasn't transformed you; it's a small permanent edit to your day. The honest payoff projection stops there. The metabolic-transformation pitch — that you'll reverse a trajectory, drop a pant size, push back diabetes by twenty years — has no trial backing in healthy adults Berry et al. 2020.

What it actually costs and where the price grows

Stelo runs about $89 for two sensors and ~28 days of wear; Libre Rio is cheaper per sensor, Lingo similar. You buy them direct from the manufacturer's site or off the pharmacy shelf — Stelo, the only one cleared in the US under genuine over-the-counter rules, can sit next to ibuprofen. Insurance does not cover the OTC product in a non-diabetic adult; budget the $90–$180 out of pocket for the full investigative course.

The trap is the subscription layer. Third-party platforms (Levels, Nutrisense, Veri, Signos, January AI) bundle the sensor with coaching, food-photo logging, and a metabolic-aesthetics dashboard at $200–$400 a year on top of the sensor cost. The platforms that built this category have a commercial interest in continuous wear, and the dashboards' "metabolic age" scores run ahead of what the evidence supports. If the wear was meant to be a four-week research project, the subscription pulls it into a year-long lifestyle expense. Decide which one you signed up for before the auto-renew.

Skin and adhesive last the full two weeks for most wearers; occasional shower, swim, gym session, hot tub all fine. Move the sensor to a different patch of arm each time. A small percentage get adhesive irritation and have to stop early.

If a CGM was your way of asking a bigger question, the adjacent reads are: fasting glucose and HbA_1c as annual screening; the post-meal walk on its own; meal order and fibre-first eating; alcohol and overnight metabolism; sleep and next-day glucose handling; ApoB as the cardiovascular risk number; fasting insulin and HOMA-IR.

Related in the handbook

Alternatives

— A CGM is the workaround when an A1c is unreliable — iron deficiency, sickle trait, kidney disease and more.

— Seeing your glucose in real time is how you flatten the spikes that damage the back of the eye. The yearly dilated exam checks whether it's working.
— For someone in the first 90 days of type 2 diabetes, a CGM turns abstract advice into your own glucose data.
— A CGM is one way to see for yourself how a sweetener swap flattens your sugar response.
— If you're trialing a metabolic supplement like berberine, a short CGM stint tells you whether it's doing anything for your glucose.
— Breakfast is the clearest experiment to run on a CGM: same food, different order, watch the spike change.
— Like a calorie app, a CGM is best read as a relative signal over a couple of weeks, not a precise daily ledger you trust to the digit.
— Food order is one of the clearest tricks a CGM will show you working on your glucose curve.
— A CGM shows you in real time what glycemic load predicts on paper.
— Before treating every glucose bump as a problem, remember normal bodies swing; an 'optimal' framing can invent issues that aren't there.
— Like a sleep tracker, the number is noisy day to day — best read as a trend over weeks, not a daily verdict.
— For someone with autoantibodies flagged by T1D screening, a CGM is an early-warning tool for the onset of diabetes.
— A CGM is a good way to test whether time-restricted eating is doing anything for your blood sugar.
— A sensor lets you see it for yourself: a ten-minute walk after dinner really does blunt the glucose spike.

1. Substance and claimed effects

A continuous glucose monitor (CGM) is a wearable biosensor — a coin-sized adhesive patch on the upper arm or abdomen with a flexible filament (about 5 mm long, hair-thin) sitting in subcutaneous interstitial fluid. The filament uses glucose oxidase chemistry to estimate glucose concentration every 1–5 minutes; results stream by Bluetooth to a phone app. Sensor wear is 14–15 days per unit. Until 2024 in the United States, all CGM systems were prescription-only and reimbursed primarily for insulin-using diabetes (Dexcom G6/G7, Abbott FreeStyle Libre 2/3, Medtronic Guardian). In March 2024 the FDA cleared Dexcom Stelo as the first over-the-counter CGM for non-insulin users FDA 2024; Abbott Lingo (consumer/metabolic-coaching framing) and Libre Rio (non-insulin diabetes framing) followed in June 2024 FDA 2024. A two-sensor pack costs roughly $89, putting four-week continuous coverage at ~$90–$180/month direct-to-consumer.

Claims about CGM use in non-diabetic adults cluster into five buckets: (1) detection of glycemic variability — peaks, swings, and time-in-range that fasting glucose and HbA_1c miss; (2) personal food-response mapping — the same meal raises glucose very differently in different people Zeevi et al. 2015; (3) exercise response and recovery — verifying that aerobic and resistance bouts blunt postprandial peaks; (4) overnight pattern — late-evening eating, alcohol, and poor sleep mapped against nocturnal glucose Tsereteli et al. 2022; (5) behaviour change via biofeedback — the device's screen as a nudge toward fewer refined carbs and more movement after meals. The entry covers the OTC, non-diabetic use case; the prescription, diabetes-management use case is alluded to as evidence base but not the substance under review here.

2. Evidence by addressing question

2a. mechanism

What the sensor measures. The filament generates an electrochemical signal proportional to glucose concentration in interstitial fluid (ISF), not blood. ISF glucose tracks blood glucose with a physiological lag of approximately 5–10 minutes, longer (10–15 min) during rapid changes Klonoff et al. 2017. Manufacturer algorithms apply a factory or one-point calibration plus smoothing; the displayed value is a model estimate, not a direct read. Accuracy is reported as Mean Absolute Relative Difference (MARD) against venous reference: modern Dexcom and Abbott devices report population MARD of 8–10% across the operational range Freckmann et al. 2019. In the euglycemic range typical of non-diabetic users (70–140 mg/dL), absolute error is often ±10–15 mg/dL on any individual reading.

What glycemic variability reflects biologically. Postprandial glucose excursions are jointly produced by carbohydrate quantity and type, gastric emptying, gut microbiota, hepatic insulin sensitivity, β-cell first-phase insulin response, prior exercise, sleep, stress, and meal timing relative to circadian phase. The same 50 g oral glucose load can produce a peak under 130 mg/dL in one healthy adult and over 180 mg/dL in another Hall et al. 2018. The Israeli PNP cohort (n=800) and the UK/US PREDICT-1 cohort (n=1,002 with twin replication) both demonstrated that personal postprandial responses to identical standardized meals vary by 2–5× across individuals and are only partly predicted by macronutrients Zeevi et al. 2015 Berry et al. 2020. This variability is real signal — the same person responds reproducibly to the same meal across days — but it does not, on its own, predict downstream disease.

Why variability is hypothesised to matter beyond mean glucose. Acute glucose fluctuations in people with type 2 diabetes activate oxidative stress pathways (8-iso-prostaglandin F_2α) independently of mean glucose Monnier et al. 2006. This mechanistic finding underwrites much of the consumer-CGM marketing pitch for non-diabetics — that suppressing spikes today reduces oxidative damage tomorrow — but the inferential leap from a 2006 hyperglycemia study to euglycemic adults remains unbridged in the trial literature.

2b. evidence

Evidence in diabetes (strong, not the entry's primary scope). CGM reduces HbA_1c and time below range relative to self-monitored blood glucose in adults with type 1 diabetes (DIAMOND, JAMA 2017: HbA_1c −1.0% vs −0.4% at 24 weeks; GOLD, JAMA 2017: between-group difference −0.43%) Beck et al. 2017 Lind et al. 2017. The MOBILE trial extended benefit to adults with type 2 diabetes on basal insulin (HbA_1c −0.4% between-group, 8 months) Martens et al. 2021. The ADA Standards of Care 2024 recommend CGM for all insulin-using diabetics and acknowledge potential benefit in non-insulin T2D ADA 2024. The Time-in-Range consensus set 70–180 mg/dL as the operational target band, with >70% TIR as the clinical goal Battelino et al. 2019; the 2023 update standardised CGM-derived metrics for trials Battelino et al. 2023.

Evidence in non-diabetic adults (sparse, observational, no hard-endpoint trials). Two reference distributions exist for "normal" CGM in healthy adults: Shah et al. (JCEM 2019, n=153 healthy adults, Dexcom G4/G6) found mean 24-hour glucose 98–99 mg/dL, time above 140 mg/dL of 2.1%, and time above 180 mg/dL of 0.1% Shah et al. 2019; Hall et al. (PLOS Biology 2018, n=57) clustered healthy individuals into three "glucotypes" (low, moderate, severe variability) and reported that 15% of nominally healthy participants spent >2% of time above 140 mg/dL despite normal HbA_1c and OGTT Hall et al. 2018. PREDICT-1 (Nat Med 2020, n=1,002) showed that postprandial glucose, triglyceride and insulin responses are weakly correlated within-person and that personal responses partly predict adiposity and inflammation markers Berry et al. 2020. Tsereteli et al. (Diabetologia 2022) reported that within the same PREDICT cohort, a single night of poor sleep raised next-morning postprandial glucose by a small but reproducible amount Tsereteli et al. 2022.

What is missing. No randomised trial has demonstrated that wearing a CGM as a non-diabetic adult reduces incident type 2 diabetes, cardiovascular events, dementia, all-cause mortality, weight, body fat, or any hard biomarker (HbA_1c, ApoB, hsCRP) over a multi-year horizon. No trial has demonstrated that CGM-guided dietary changes outperform standard dietary advice for any endpoint in non-diabetics. The case for non-diabetic CGM use is therefore inferential — mechanism + diabetes-trial extrapolation + observational variability findings — not directly evidenced.

2c. protocol

Sensor placement and wear. Upper outer arm is the validated site for Dexcom and Abbott consumer CGMs. Clean and dry skin; alcohol wipe; press the applicator firmly. Warm-up period before first reading is 30–60 min (Stelo: 30 min; Libre Rio: 60 min). Wear is 14–15 days per sensor; daily activities including showering and swimming are tolerated. Replacement sensors should be placed on a different patch of skin to avoid local irritation.

Typical investigative protocol for a non-diabetic. A useful structured approach: (1) first 2–3 days as a baseline — eat and live normally, observe overnight floor, fasting morning value, typical postprandial pattern; (2) days 3–7 — log meals with photos and approximate composition; flag any peak above ~140 mg/dL or any rapid swing; (3) days 7–10 — test specific hypotheses, e.g., the same meal eaten alone vs. preceded by 10 minutes of walking, white rice vs. basmati, breakfast at 7am vs. 10am; (4) days 10–14 — observe the night/exercise interaction (alcohol + late dinner, hard workout + early dinner). Two sensors (4 weeks) is enough for most non-diabetic users to build a useful personal map; beyond that, marginal information falls steeply.

What "normal" looks like. Reference values from healthy adult cohorts: 24-hour mean glucose 95–105 mg/dL; fasting 70–100 mg/dL; postprandial peak typically <140 mg/dL; time-above-140 typically <3% of the day; coefficient of variation (CV) under 17% considered low-variability Shah et al. 2019 Battelino et al. 2019.

2d. contraindications

The device itself is low-risk: local skin irritation from adhesive (5–10% of wearers), rare insertion-site infection. The genuine contraindications are behavioural and psychological. Adults with a current or past eating disorder (anorexia, bulimia, orthorexia, binge-eating disorder) should not wear a CGM without clinician supervision: the device produces a continuous stream of numerical feedback that maps trivially onto food restriction and ritualised eating, and clinical case series describe worsening of restrictive eating patterns. Anxious health-monitoring patterns (somatic preoccupation, illness-anxiety) likewise contraindicate. Patients on diabetes medication (sulfonylureas, insulin) should not initiate or modify regimens based on consumer-CGM readings without their prescriber; the device's accuracy in hypoglycemic range (<70 mg/dL) is poorer and the lag matters more Klonoff et al. 2017. Pregnant women: consumer CGMs are not validated for gestational diabetes management.

2e. misconceptions

"My peak above 140 means I'm pre-diabetic." No. Even healthy young adults regularly cross 140 mg/dL after high-glycemic meals; the Shah and Hall cohorts establish this empirically. A single spike is a normal physiological response, not a disease marker. Time above 140 mg/dL exceeding 4–5% of total wear time on multiple sensors in a row, in combination with fasting glucose >100 mg/dL or HbA_1c >5.7%, is the conventional flag for prediabetes — and that flag belongs to a clinician.

"The number on the screen is my blood sugar." Not exactly — it is a smoothed, lagged estimate from interstitial fluid Klonoff et al. 2017. Sudden swings on the app during exercise, after compression (sleeping on the sensor), or during sensor warm-up are often artefact. Two simultaneous fingersticks would show 10–15 mg/dL of disagreement on most consumer-grade CGMs.

"Flat is best." The "flat-line evangelism" of consumer CGM marketing — that any postprandial rise is bad — has no support in the trial literature. Modest postprandial excursions are how a normal, healthy person processes carbohydrate. Pathological is sustained elevation, repeated severe excursions, and slow return to baseline — not the existence of a rise.

"CGM data tells me what to eat." Within-person reproducibility of meal responses is real Zeevi et al. 2015, but the link between blunting a personal spike and any clinically meaningful outcome remains unproven in non-diabetics. The most defensible interpretation is "this informs your menu of high-glycemic foods" — not "this is your personalised disease-prevention plan."

2f. audience

The OTC market segments the device into roughly four user types: (1) the metabolically-curious adult (mid-20s to mid-50s, no diagnosed diabetes) wanting to map food and exercise responses — the dominant marketing target; (2) the family-history-of-T2D adult using the CGM as an early-warning system alongside annual labs; (3) the weight-management user pairing CGM with calorie restriction; (4) the endurance athlete optimising race-day fuelling. Real evidence supports use case (2) the most weakly — a CGM is not a screening tool; HbA_1c and fasting glucose remain the validated screens. Use case (4) has thin observational support and is genuinely useful for the specific narrow question of "did I bonk because I ran out of glycogen." Use cases (1) and (3) are the consumer pitch and the area where trial evidence is most absent.

2g. alternatives

Fasting glucose and HbA_1c (annual or biennial blood draw). Cheap, validated, the diagnostic standard for screening and monitoring of dysglycemia. Misses postprandial excursions and intra-day variability — which is the entire pitch for CGM in non-diabetics — but catches the clinical conditions that actually matter on years-to-decades timescales.

Oral glucose tolerance test (OGTT, 2-hour 75g). The reference standard for impaired glucose tolerance and gestational screening. One snapshot, one challenge, validated thresholds.

Continuous metabolic dashboards without a sensor. Pairing food logs with periodic fingersticks recovers most of the dietary-feedback signal at a fraction of the cost — but with much higher behavioural friction (10+ pokes/day to map a single meal).

Smartwatch-class non-invasive "glucose" tracking. No consumer wearable has FDA clearance for non-invasive glucose measurement as of 2024–2025. Watches and rings advertising "glucose insights" are inferring trends from other signals (heart rate variability, skin temperature) — useful or not, this is not glucose measurement.

2h. failure-modes

Behaviour change runs out at the sensor. The dominant failure mode in practice: dietary changes prompted by visible CGM spikes regress within weeks of removing the sensor. The biofeedback effect is real while the screen is in the user's pocket; persistence without the sensor is the open question, and longitudinal data is absent.

Anxiety amplification. Visible numerical feedback on every meal triggers somatic preoccupation in a sub-population. The Reddit r/CGM and r/Glucose communities describe a pattern of users abandoning the device because "every meal felt like a test."

Misinterpretation of normal physiology as disease. A user with a 160 mg/dL peak after a doughnut who concludes they are pre-diabetic. The cohort data shows this peak is unremarkable in healthy adults Hall et al. 2018; the consumer apps frequently frame any 140+ value as concerning.

Sensor artefact mistaken for pathology. Compression lows (sleeping on the sensor produces a false low), warm-up errors (first 12–24 hours wildly inaccurate), and rapid-swing lag (interstitial value behind venous during exercise) generate readings that look like medical events.

Disordered eating worsened. For a user with subclinical or undiagnosed eating-disorder traits, CGM-driven food restriction can entrench restrictive patterns. Clinician case-series, not formal trials, document this; it is plausible enough on first principles that the contraindication is uncontroversial.

2i. practicalities

Cost. Stelo: ~$89 for two sensors (28–30 days of wear). Lingo: ~$89 per sensor (14 days). Libre Rio: ~$45 per sensor. Continuous coverage runs $90–$180/month direct-to-consumer; insurance does not cover OTC CGMs in non-diabetics. A typical 2–4-week investigative course is $90–$180 total.

App ecosystems. Each manufacturer ships its own app (Stelo, Lingo, Libre Rio). Third-party platforms (Levels, Nutrisense, January AI, Veri) layer coaching, food-photo logging, and analytics on top — often at $200–$400/year subscription on top of the sensor cost. The third-party layer is where most consumer-CGM critique lands: the analytics and "metabolic age" scores frequently outrun the underlying evidence.

Skin and wear. The adhesive lasts a full 14–15 days for most users; gym workouts, showers, and hot tubs are tolerated. Overskin (sensor patches, Tegaderm) is common for athletes. Replace on a different patch of upper arm.

Data export. Most consumer apps allow CSV export of raw readings — useful for users who want to do their own analysis or share with a clinician. Stelo specifically does not allow alarm setting (regulatory constraint of the OTC clearance).

2j. stakes (what continues if a non-diabetic ignores their glycemic pattern)

For the typical reader — non-diabetic, no family history of T2D, normal weight or modest overweight — the stakes of not wearing a CGM are essentially zero on any reader-relevant timescale. The clinically validated screens (fasting glucose annually, HbA_1c if indicated) catch the conditions that matter. A reader with strong family history, prior gestational diabetes, or rising fasting glucose has higher stakes but the appropriate response is clinical follow-up, not consumer CGM.

2k. payoff (what changes for a non-diabetic who wears a CGM)

Within the wear window: identification of personal high-glycemic meals (often surprising — a "healthy" smoothie may peak harder than an omelette); confirmation of the post-meal-walk effect on the user's own data; visualisation of the nocturnal floor and how alcohol or a late dinner perturbs it; reproducible measurement of how much exercise actually blunts a postprandial rise. For users without a history of disordered eating or health anxiety, this is generally a useful informational episode — one or two two-week sensors, then return to lower-cost monitoring.

Beyond the wear window: trial evidence for sustained behaviour change, biomarker improvement, or hard-endpoint benefit in non-diabetics is absent. The honest payoff projection is "a sharper personal model of carbohydrate response and a few persistent behavioural shifts (the post-meal walk, the swapped breakfast)" — not metabolic transformation.

2l. out-of-scope

Adjacent topics that bear on the reader but lie outside this entry: fasting glucose and HbA_1c as screening tests; the post-meal walk; dietary fibre and protein order at meals; sleep and glucose regulation; alcohol's effect on overnight glucose; meal timing and circadian metabolism; insulin resistance assessment beyond glucose.

3. The credibility range

The optimist case. Glycemic variability is a real, biologically grounded phenomenon (Monnier 2006 oxidative-stress link Monnier et al. 2006); individual postprandial responses vary 2–5× to identical meals (PNP, PREDICT Zeevi et al. 2015 Berry et al. 2020); 15% of nominally healthy adults show patterns that fasting glucose and HbA_1c miss Hall et al. 2018; in-diabetes CGM trials are unambiguously positive on glycemic endpoints Beck et al. 2017 Lind et al. 2017 Martens et al. 2021; sleep, exercise, and meal-timing effects on glucose are reproducible at the individual level Tsereteli et al. 2022. The biofeedback mechanism — see your own data, change your behaviour — is reasonable on first principles. A 2–4-week structured wear is cheap (~$90–$180), low-risk, and information-rich. The combination of "real phenomenon + cheap measurement + plausible behavioural lever" justifies the use case for a curious non-diabetic adult.

The skeptic case. No randomised trial has shown that non-diabetic CGM use improves any hard endpoint or any biomarker beyond the wear window. The annual screening tests (fasting glucose, HbA_1c) catch what actually matters for population health at a fraction of the cost. The cohort data showing healthy adults occasionally exceed 140 mg/dL is being read by consumer apps as pathology, and the resulting "flat-line evangelism" pathologises normal physiology. Behaviour change observed during wear regresses post-removal in the available longitudinal data. A non-trivial sub-population is harmed: anxiety amplification, disordered-eating entrenchment, false reassurance from a "normal" pattern that obscures a different problem. The commercial layer (Levels, Nutrisense, manufacturer apps) routinely outruns the evidence with "metabolic age" scores and personalised-nutrition pitches built on extrapolation. The cost of "course is $90–$180" undersells the typical user pattern of multi-month subscription. Until a trial shows that non-diabetic CGM use changes a meaningful endpoint, the device is best framed as educational with caveats, not as a health intervention.

The author's call. The two-to-four-week investigative use case is defensible — a non-diabetic adult, no eating-disorder history, mild curiosity about personal food responses, is unlikely to be harmed and likely to learn something specific and persistent (post-meal walk works; their personal highest-glycemic meal is X). Past four weeks, marginal information falls steeply and the case weakens; continuous indefinite wear in a non-diabetic adult is not supported by evidence and risks anxiety amplification. Evidence rating: 2 — strong in diabetes, sparse and observational outside it, no hard endpoints. Controversy rating: 3 — active debate among endocrinologists, performance-medicine clinicians, and dietitians about whether OTC CGMs are net-helpful for non-diabetic adults.

4. Stakeholder and incentive map

Manufacturers. Dexcom and Abbott have a multi-billion-dollar revenue stream growing into a market roughly 10× larger than insulin-using diabetes. OTC clearance was the strategic move. Direct commercial interest in the expansive use case.
Third-party software platforms. Levels (acquired customers and exited founder roles), Nutrisense, January AI, Veri, Signos. Bundle CGM with coaching at $200–$400/year. Strongest commercial interest in framing CGM as a year-round metabolic-health intervention rather than a 2-week investigative tool.
Performance / longevity medicine. Influencer-physicians (Attia, Means siblings, Lustig) actively recommend CGM for non-diabetics. Variable financial entanglement with the third-party platforms.
Endocrinology and primary-care professional societies. ADA endorses CGM for insulin-using diabetes and acknowledges utility in non-insulin T2D ADA 2024; non-diabetic use is largely outside guideline scope. Generally cautious.
Dietitians and eating-disorder clinicians. Strongest organised skeptic voice — public statements warning about disordered-eating amplification.
Insurers and regulators. Do not reimburse OTC CGMs in non-diabetics. Implicit signal that the evidence base does not justify the cost from a population-health perspective.

5. Population variability

Response to identical meals. The defining finding: 2–5× variation in postprandial peak across healthy adults to the same standardised meal, partly heritable, partly microbiome-mediated, partly explained by prior sleep and exercise Zeevi et al. 2015 Berry et al. 2020 Hall et al. 2018.
Age. Postprandial peaks are typically higher and slower-to-return in older adults; reference ranges from young cohorts may under-estimate "normal" for users in their 60s.
Sex and life stage. Menstrual cycle, perimenopause, and post-menopause shift insulin sensitivity; pregnancy moves the entire glucose distribution and consumer CGMs are not validated for gestational management.
BMI and adiposity. Higher visceral adiposity correlates with higher fasting glucose, larger postprandial peaks, and slower recovery — sometimes visible on CGM before fasting glucose rises into prediabetic range.
Athletes. Endurance-trained individuals show lower mean glucose and faster recovery; weight-trained individuals can show transient post-workout elevation that is not pathological.
Ethnicity. Glycemic patterns and HbA_1c-glucose relationships differ across ancestry groups; non-diabetic CGM reference data is dominated by US and European cohorts and may not generalise to South Asian, East Asian, or African populations where T2D risk patterns differ.

6. Knowledge gaps

No RCT of OTC CGM use in non-diabetic adults with any biomarker or hard endpoint (HbA_1c, weight, ApoB, hsCRP, incident T2D) over >1 year.
No trial comparing CGM-guided dietary advice to standard dietary advice in non-diabetics.
No clean data on persistence of CGM-induced behaviour change after sensor removal.
No incidence data on CGM-precipitated disordered eating or health anxiety at population scale (case series only).
Limited evidence on whether glycemic-variability metrics in non-diabetic adults predict future T2D incidence independently of fasting glucose and HbA_1c.
The Time-in-Range threshold (70–180 mg/dL) is calibrated to diabetes management and may be inappropriately lax as a "metabolic health" benchmark for non-diabetics.
No data on whether multi-month or indefinite wear in non-diabetics produces net benefit or net harm. Evidence change that would shift the author's call: a properly powered, multi-year RCT of structured CGM use plus dietary counselling vs. dietary counselling alone, with HbA_1c and weight as co-primary endpoints; or longitudinal data showing that CGM-detected variability above 140 mg/dL in nominally healthy adults predicts incident T2D independently of fasting glucose.

Scope. Entry covers OTC, non-diabetic adult use (Stelo, Lingo, Libre Rio) because that is what the consumer pitch is and what the brief named. The strong diabetes-trial evidence (DIAMOND, GOLD, MOBILE) is treated as load-bearing context — the case for non-diabetic use leans on the strength of those trials by extrapolation — but the prescription, insulin-tied use case is not the substance under review and was deliberately not expanded into its own section. If the catalogue later wants a separate CGM in diabetes management entry, it should be a distinct page; the rating ladder for that entry would be entirely different (evidence 5, controversy 0, much higher health_short_term and longevity scores).

Brief vs coverage. The topic brief named five consequences — glycemic variability, food and exercise responses, overnight patterns, dietary feedback, and the limits of evidence for non-diabetic benefit. All five are covered: variability and food responses in mechanism and evidence; exercise and overnight patterns in protocol and payoff; dietary feedback as the spine of the protocol; the evidence-limits theme runs through evidence, misconceptions, and payoff. Nothing was silently dropped.

Rating difficulties.

Evidence 2. Tension here: the diabetes evidence is genuinely 5; the non-diabetic OTC evidence is genuinely 1–2 (observational variability data and mechanism, no RCT for any hard endpoint). The score reflects the substance as scoped — OTC, non-diabetic — and is intentionally not the diabetes 5.
Energy 1 and focus 1. These ride on the Hall 2018 glucotype data plus mechanism, not on an RCT in healthy adults. Defensible because (a) ~15% of healthy adults run the high-variability pattern, (b) post-prandial reactive dips are a known subjective phenomenon, (c) the article body honestly flags the effect as small and behaviour-mediated. If the editorial bar wants RCT-only support for benefit scores, these drop to 0.
Sleep 0, mood 0. Considered scoring sleep 1 (CGM surfaces alcohol/late-eating overnight-floor effects) but the substance — the device — does not produce a sleep effect; any sleep benefit is a behavioural second-order through the data. Same logic for mood.
Longevity 0. Considered 1 by extrapolation but there is no longevity data for non-diabetic CGM use, and scoring 1 would conflict with the article's honest "no hard endpoint demonstrated" framing.
Cost_burden 2. Scored to the 2–4 week investigative course (~$90–$180), which is what the article protocol prescribes. Continuous indefinite wear with a coaching subscription would be cost 3; that is not the recommended pattern.
Controversy 3. Active debate among endocrinologists, dietitians (eating-disorder side), and performance-medicine clinicians. Not 4 because the boundaries of the dispute are narrow (everyone agrees CGM works in diabetes; the disagreement is about non-diabetic use and pathologisation risk).

Hard editorial calls. Pitched the article as action: test and cadence: course rather than do/as-needed on purpose — the defensible use case is a bounded research project, not a permanent monitoring habit. The "two-or-three-sensor course" framing is the article's central editorial position; if the consensus shifts to "wear forever," that scoring and framing both need to change.

Future links. Once they exist, this entry should cross-link to: fasting glucose / HbA_1c as screening; the post-meal walk; meal order and fibre-first eating; alcohol and overnight metabolism; sleep and next-day glucose; ApoB and cardiovascular risk; fasting insulin and HOMA-IR.

Separate-entry candidates surfaced during writing. CGM in type 1 diabetes management (insulin pump integration, hybrid closed-loop systems, the DIAMOND/GOLD/CONCEPTT trial line). Time-in-range as a clinical metric. The "metabolic age" / Levels-Nutrisense business-model critique as its own consumer-health-tech entry.